Compare NWFL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NWFL | CTNM |
|---|---|---|
| Founded | 1870 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.2M | 489.4M |
| IPO Year | 1996 | 2024 |
| Metric | NWFL | CTNM |
|---|---|---|
| Price | $30.76 | $11.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $33.00 | $19.00 |
| AVG Volume (30 Days) | 17.1K | ★ 197.5K |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 15150.00 | 0.46 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $7,999,000.00 | N/A |
| Revenue This Year | $34.35 | N/A |
| Revenue Next Year | $5.55 | N/A |
| P/E Ratio | $87.57 | ★ N/A |
| Revenue Growth | ★ 8.11 | N/A |
| 52 Week Low | $23.70 | $3.72 |
| 52 Week High | $32.36 | $16.33 |
| Indicator | NWFL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 42.83 |
| Support Level | $28.95 | $11.82 |
| Resistance Level | $31.00 | $13.40 |
| Average True Range (ATR) | 0.80 | 0.93 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 47.61 | 32.56 |
Norwood Financial Corp is a U.S.-based bank holding company. It offers various personal and business credit services, trust and investment products, and real estate settlement services to consumers, businesses, nonprofit organizations, and municipalities in each of the communities that the bank serves. The bank also manages automated teller machines at its branch location. It serves the Pennsylvanian counties of Wayne, Pike, Monroe, and Lackawanna, as well as Susquehanna County.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.